

1 *Acute and Subacute Ischemia of Lower Limbs: Angiography and Peripheral Hemodynamics.*  
2 *Bulvas M, Sommerová Z.*  
3

4

## 5 **Acute and Subacute Ischemia of Lower Limbs:** 6 **Angiography and Peripheral Hemodynamics**

7

8 Running title: Acute and subacute limb ischemia

9 Miroslav Bulvas, MD. PhD. Assoc. Prof.

10 Zuzana Sommerová, MD. PhD.

11

12 Affiliations:

13 Miroslav Bulvas, Department of Surgery, Division of Angiology, University Hospital

14 Královské Vinohrady, Third Faculty of Medicine, Charles University (address: Šrobárova 50,  
15 100 34, Prague 10, Czech Republic)

16

17 Zuzana Sommerová, Center for Cardiovascular Prevention, First Faculty of Medicine and  
18 Thomayer Hospital, Charles University (address: Vídeňská 800, 140 59 Prague 4, Czech  
19 Republic), email: [zuzanasommerova@mybox.cz](mailto:zuzanasommerova@mybox.cz)

20

21

22 Corresponding author: Miroslav Bulvas, email: [bulvasm@seznam.cz](mailto:bulvasm@seznam.cz)

23

24

[miroslav.bulvas@lf3.cuni.cz](mailto:miroslav.bulvas@lf3.cuni.cz)

25

phone: +420 603426473

26

address: U Michelského mlýna 35, 140 00 Prague 4,  
27 Czech Republic

28

ORCID iD: 0000-0003-4211-6696

29

### 30 Acknowledgments

31 The authors thank Candance McClure (NAMSA, Toledo, OH, USA) and Marian  
32 Rybář (MATSTAT, Prague, Czech Republic) for statistical expertise.

33

34 Declaration of Conflicting Interests: The authors have no potential conflicts of interest with  
35 respect to the research, authorship, and/or publication of this article.

36

### 37 Funding

38 The authors received no financial support for the research, authorship, and/or  
39 publication of this article.

40

41

42

43

44 **ABSTRACT**

45

46 **Objective:** To identify pretreatment characteristics related to ischemia severity and symptoms  
47 duration in patients with acute (ALI) and subacute lower limb ischemia (SLI).

48 **Methods:** Comparative study, a part of prospective, single-arm, single-center trial of 316  
49 consecutive patients with threatened extremities (all-comers, mean age: 70.9±12.0 years,  
50 range: 23-96; 184 men) of whom 99.4 % suffered from acute or subacute supratibial  
51 occlusions (target occlusions).

52 **Results:** Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented  
53 in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The  
54 value of ABI related to the number of occluded tibial arteries. Occlusion locations associated  
55 with ALI (IIA+IIB) were the aortoiliac segment and/or profunda femoris. Furthermore, ALI  
56 subjects presented additional infrapopliteal occlusion (acute and/or subacute), smaller number  
57 of patent tibial arteries and lower ABI.

58 **Conclusion:**

59 Anatomically, the most important factor related to the ischemia severity and symptoms  
60 duration was the status of infrapopliteal vascular bed. The number of acutely, subacutely or  
61 chronically occluded tibial vessels was related to clinical categories of ALI and SLI and to  
62 ABI. This suggests that tibial reperfusion can be essential for the salvage of threatened limb  
63 and should be always considered.

64

65

66

67

68

69

70

71 INTRODUCTION

72 Acute lower limb ischemia (ALI) is a critical vascular emergency that endangers the  
73 affected extremity and puts the patient's life at risk. It is defined as a sudden decrease in or  
74 worsening of limb perfusion that has been present for 14 days or less and causing a potential  
75 threat to limb viability<sup>1,2</sup>.

76 The clinical presentation of ALI is not single and varies from viable to irreversibly  
77 damaged extremity. The limb can be threatened immediately after the symptoms origin or  
78 later when ischemia progresses, steadily or in steps. The fact that suddenly developed  
79 ischemia can escalate during the time period longer than 2 weeks, led many authors to use  
80 the term "subacute limb ischemia" (SLI) to distinguish the unstable and developing condition  
81 from the chronic, stable ischemic status. The guidelines<sup>3,4</sup> defined SLI by symptoms duration  
82 longer than 14 days, and lasting up to 3 months.

83 The pre-treatment factors, reported in the literature<sup>5,6</sup> to influence the mortality and  
84 amputation rates were high age, female gender, non-Caucasian race, comorbidities (diabetes,  
85 malignancy, neurological disorders, coronary heart disease, congestive heart disease),  
86 multilevel occlusion, more proximal occlusions, limb ischaemia severity, treatment risk and  
87 urgency, tissue damage, repeated ALI attacks, absence of early anticoagulation and delay in  
88 diagnosis and revascularization. However, their role and incidence may differ in patients with  
89 different clinical presentation.

90 Because the same initial treatment techniques (open surgery, catheter-directed  
91 thrombolysis, mechanical thrombectomy) are used in patients with ALI or SLI<sup>7</sup>, different  
92 number of patients with SLI and those with ALI categorized as type I (viable extremity), IIA  
93 (marginally threatened) or IIB (immediately threatened) have been often grouped in ALI  
94 cohorts in studies to date analyzing surgical and/or endovascular treatment outcomes. To  
95 understand whether such a grouping can affect the overall results and comparability among  
96 the studies, it is important to learn more about characteristic of individual clinical categories.

97 Closer knowledge is necessary for better understanding the high mortality and amputation  
98 rates, and the factors associated with or responsible for clinical presentation, serious events  
99 and technical failure of therapeutic intervention.

100 The aim of this study was to identify the relations of ischemia severity and/or  
101 symptoms duration with age, gender, comorbidities, clinical presentation, arterial occlusion  
102 aetiology, vascular anatomy and peripheral hemodynamics in patients with threatened lower  
103 extremity due to ALI (IIA, IIB) or SLI. Specifically, we focused on the role of infrapopliteal  
104 arterial patency in 316 patients (all-comers) of whom 99.4 % primarily suffered from acute  
105 or subacute supratibial occlusions (target occlusions).

## 106 MATERIAL AND METHODS

107 Our study was a single-centre, prospective, single-arm trial performed during the time  
108 interval 2009–2015 with two main goals. The first part documented the efficacy, safety and  
109 applicability of endovascular removal of occlusive material as the initial treatment in patients  
110 with limb threatening ALI and SLI. It was already published<sup>8</sup>.

111 In this report, we focused on pre-treatment difference between clinical categories (ALI  
112 vs. SLI, ALI IIB vs. ALI IIA, females vs. males, thrombotic occlusion vs. embolism). We  
113 compared demographic data, frequencies of risk factors and comorbidities, clinical data,  
114 ankle-brachial pressure index (ABI) and vascular anatomy characteristics (Table 1, 2).

115 The target lesion and vascular anatomy information was obtained by digital  
116 subtraction angiography in all patients. No therapeutic interventions were performed or tested  
117 in this part of the study.

118 The study included 316 consecutive patients (all-comers, 184 men, mean age:  $70.9 \pm$   
119  $12.0$  years): 202 subjects with ALI (114 men, mean age:  $72.6 \pm 12.2$ , mean symptoms  
120 duration:  $4.13 \pm 4.47$  days; 146 patients categorized as IIB of the Rutherford classification for  
121 acute limb ischaemia<sup>2</sup>; 56 patients of the category IIA) and 114 patients with SLI (70 men,

122 mean age:  $67.9 \pm 10.9$  years; mean symptoms duration:  $44.3 \pm 27.3$  days). SLI patients were  
123 categorized on the basis of the Rutherford classification for chronic limb ischemia <sup>2</sup> (38  
124 patients: category 3; 50 patients: category 4; 26 patients: category 5). Critical limb ischemia  
125 was diagnosed in 74 patients with SLI according to established guidelines <sup>1,9,10</sup>.

126 Target, supratibial occlusions (acute or subacute) were located in aortoiliac arterial  
127 segment, femoropopliteal segment, deep femoral artery, bypasses (aortofemoral,  
128 femoropopliteal, femorofemoral) and leg of bifurcation stentgraft (Table 2) in 99.4 % of  
129 patients. Isolated infrapopliteal occlusions were detected in two patients (0.6 %).

130 Occlusion cause was determined on the basis of clinical manifestation, angiographic  
131 findings<sup>11</sup>, resistance to guidewire penetration and occurrence of underlying lesion after the  
132 clot removal. Thrombotic occlusion was diagnosed in 256 (81.0 %), and embolism in 60 (19.0  
133 %) patients.

134 The University Hospital Královské Vinohrady and the Third Medical Faculty of the  
135 Charles University Centralized Institutional Review Board approved the study protocol and  
136 informed consent form (identifier: EK/IV-2/2009). The study was conducted in accordance  
137 with Declaration of Helsinki, and all patients provided written informed consent. The trial was  
138 registered with the International Standard Randomized Controlled Trials Number registry  
139 (ISRCTN 154967770). The inclusion criteria allowed enrolment of adult patients with ALI  
140 (symptoms duration  $\leq 14$  days) or SLI (symptoms duration  $>14$  days and  $\leq 3$  months), severe  
141 claudication, ischemic rest pain, sensorimotor deficit and/or tissue defects. Patients presented  
142 from a variety of sources – overflow from other urban institutions, remote community  
143 hospitals, physician referral, and self-presenting. The exclusion criteria were irreversible  
144 ischemia and viable extremity.

145 Statistical analysis: continuous data are presented as the mean  $\pm$  standard deviation  
146 (SD). Categorical data are given as the number (percentage). Continuous variables were

147 compared using a paired or unpaired t test or Wilcoxon rank sum test, as appropriate.  
148 Categorical variables were analyzed using a 2 -sided chi-square or Fischer exact test, as  
149 appropriate. For analysis of variance (ANOVA), Welch´s test for unequal sample sizes was  
150 used. The threshold of statistical significance was  $p < 0.05$ . Statistical analyses were  
151 performed using SAS software (version 9.4; SAS Institute, USA) and STATSOFT software  
152 for Welch´s test (Statistica, version 10, USA).

153

## 154 RESULTS

### 155 *Anatomy*

156 The presence of acute or subacute supratibial arterial occlusions was documented in  
157 314 (99.4 %) of 316 patients with threatened lower limbs due to ALI and SLI. Mean length  
158 of supratibial occlusion was greater in group with ALI (244.6 mm) vs. SLI (202.0 mm),  
159  $p=0.0159$  and in patients with thrombotic cause of the occlusion (246.6 mm) vs. embolism  
160 (155.0 mm,  $p<.0001$ ).

161 The most frequently occluded (acutely or subacutely) locations were the  
162 femoropopliteal segment (in 73.1 % of 316 patients) and femoropopliteal bypass (22.8%).  
163 Significant difference in frequency of femoropopliteal segment and femoropoplital bypass  
164 occlusion was not documented between patients with ALI vs. SLI and ALI IIB vs. ALI IIA  
165 (Table 1).

166 The aortoiliac segment occlusion was detected in 11.1 % of all patients, with higher  
167 incidence in those with ALI (13.9 %) vs. SLI (6.1 %,  $p=.0401$ ) (Table 2). The incidence of the  
168 deep femoral artery occlusion was higher in patients with ALI vs. SLI (12.9 vs. 5.3 %,  $p=0.0332$ ),  
169 embolism vs. thrombosis (23.3 vs. 7.0 %,  $p=.0006$ ) and females vs. males (15.2  
170 vs. 6.5%,  $p=.0142$ ) (Table 2).

171           Infrapopliteal occlusion (acute or subacute) additional to occlusion located  
172           supratibially was documented in 61.7 % of all patients (ALI + SLI) with higher frequency in  
173           patients with ALI (68.3 %) vs. SLI (50.0 %,  $p=.0017$ ), ALI IIB (72.6 %) vs. ALI IIA (57.1 %,  $p=.0427$ ) and embolism (73.3 %) vs. thrombosis (59.0 %,  $p=.0403$ ) (Table 2, 4, 6).

175           Infrapopliteal occlusion (acute, subacute and chronic; segmental or total) in one, two  
176           or three tibial vessels was detected in 86.1 % of 316 patients with significant difference  
177           between ALI (90.6 %) vs. SLI (78.1 %,  $p=.0036$ ) subjects. All tibial vessels occluded were  
178           documented in 33.3 % of SLI and 62.4 % of ALI patients ( $p=.0001$ ) (Fig. 1).

179           Higher mean number of patent (without acute, subacute or chronic occlusions) tibial  
180           vessels was detected in patients with SLI (1.3) vs. ALI (0.7,  $p<.0001$ ), ALI IIA (1.4) vs. ALI  
181           IIB (0.4,  $p<.0001$ ), thrombosis (1.0) vs. embolism (0.4,  $p<.0001$ ) (Table 2, 4, 6).

182           Higher incidence of the femoropopliteal segment occlusion was established in subjects  
183           with embolism (95.0 %) vs. thrombosis (68.0 %,  $p<.0001$ ) and in female group (79.5 %) vs.  
184           males (68.5 %,  $p=.0296$ ).

185           Higher frequency of the femoropopliteal bypass occlusion was detected in the male  
186           group (28.8 %) vs. females (14.4 %,  $p=.0027$ ) and patients with thrombotic occlusion (27.7  
187           %) vs. embolism (1.7 %,  $p<.0001$ ) (Table 6, 7).

188

### 189 ***Ankle-brachial index***

190           Generally, the mean ABI was low (0.1) in the group of patients with ALI and SLI  
191           before treatment. Its value was higher in patients with SLI (0.22) vs. those with ALI (0.08,  
192            $p<.0001$ ), in subjects with ALI IIA (0.2) vs. ALI IIB (0.0,  $p<.0001$ ) and in patients with  
193           thrombosis (0.14) vs. embolism (0.07,  $p=.0016$ ) (Table 2, 4, 6). In subgroup with ABI ranged  
194           from 0.0 to 0.1, the patients with ALI were in majority (71.2 %). Patients with SLI dominated  
195           in the subgroups with ABI value from 0.2-0.5 (Fig 2).

196 The value of ABI significantly correlated ( $p<.001$ ) with the number of patent calf  
197 vessels in subjects with ALI or SLI (Fig. 3,4).

198

199 ***Target occlusion origin: embolism vs. thrombosis***

200 Embolism as the cause of target supratibial occlusion was detected in 19 % of patients  
201 with ALI+SLI. This cause was more frequent in patients with ALI (24.8 %) vs. SLI ((8.8 %,  $p=.0005$ ), ALI IIB (28.8%) vs. ALI IIA (14.3 %,  $p=.0442$ ) and in females (29.5 %) vs. males  
202 (11.4 %,  $p<.0001$ ) (Table 2, 3, 7).

204 In comparison with thrombotic lesions, the embolic occlusions were shorter in average  
205 (155 vs. 246.6 mm,  $p<.0001$ ) and they were localized more frequently in the femoropopliteal  
206 segment (95.0 vs. 68.0 %,  $p<.0001$ ) and/or the deep femoral artery (23.3 vs. 7.0 %,  $p=.0006$ )  
207 (Table 6).

208 In patients with embolic supratibial closure, higher number (73.3 vs. 59.0 %,  $p=.0403$ )  
209 of those with additional occlusions (acute, subacute, chronic; embolic or thrombotic) located  
210 infrapopliteally was detected. Additionally, these subjects presented lower number of patent  
211 calf vessels (0.4 vs. 1.0,  $p<.0001$ ) and lower ABI (0.07 vs. 0.14,  $p=.0016$ ).

212 Embolism was also associated with higher age (73.7 vs. 70.2 years,  $p=.0054$ ), higher  
213 incidence of female gender (65.0 % vs. 36.3 %,  $p<.0001$ ), cardiac disease (61.7 vs. 37.5 %,  $p=.0008$ ), arrhythmias (51.7 vs. 19.5 %,  $p<.0001$ ), ALI (83.3 vs. 59.4 %,  $p=.0005$ ) and ALI  
214 IIB (84.0 vs. 68.4 %,  $p=.0442$ ).

216 On the other hand, patients with thrombotic occlusion presented more frequent male  
217 gender (63.7 vs. 35 %,  $p<.0001$ ), positive smoking history (59.8 vs. 31.7 %,  $p<.0001$ ), SLI  
218 (40.6 vs. 16.7 %,  $p=.0005$ ), ALI IIA (31.6 vs. 16 %,  $p=.0442$ ), claudication (32.4 vs. 15 %,  $p=.0071$ ), critical limb ischaemia (26.6 vs.10 %,  $p=.0062$ ), tissue defect (17.2 vs. 5 %,  $p=.0151$ ), in-stent occlusion (27.7 vs. 5 %,  $p<.0001$ ), femoropopliteal bypass occlusion (27.1



221 vs. 1.7 %,  $p<.0001$ ) higher number of patent calf vessels (1.0 vs. 0.4,  $p<.0001$ ) and higher  
222 ABI (0.14 vs. 0.07,  $p=.0016$ ) (Table 5,6).

223

#### 224 ***Risk factors and concomitant disease***

225 Comparison between patients with SLI and ALI detected significantly higher  
226 frequency of the smoking history (64.0 vs. 49.0 %,  $p=.0134$ ), claudication (53.5 vs. 15.3 %,  $p<.0001$ ) and tissue defect (22.8 vs.10.4 %,  $p=.0047$ ). The ALI patients were older (mean age:  
228 72.6 vs. 67.9 years,  $p=.0005$ ), with longer target lesion (mean length: 244.6 vs. 202.0 mm,  $p=.0159$ ), higher frequency of rest pain (83.7 vs. 57.9 %,  $p<.0001$ ), embolism (24.8 vs. 8.8 %,  $p=.0005$ ), arrhythmias (30.7 vs. 16.7 %,  $p=.0071$ ). A higher statistical trend toward increased  
231 incidence of cardiac disease (46.0 vs. 35.1 %,  $p=.0749$ ), cerebrovascular disease (28.2 vs.19.3  
232 %,  $p=.0809$ ) and renal insufficiency (26.7 vs. 17.5 %,  $p=.0726$ ) was detected in ALI subjects  
233 (Table 1,2).

234 Comparison between ALI patients with immediately (IIB) and marginally (IIA)  
235 threatened extremities detected significantly higher frequency of diabetes (36.3 vs. 21.4 %,  $p=.0452$ ), rest pain (91.8 vs. 62.5 %,  $p<.0001$ ), embolism (28.8 vs. 14.3 %,  $p=.0442$ ) in II B  
237 subjects, together with lower mean number of patent calf vessels ( $0.4\pm 0.9$  vs.  $1.4\pm 1.1$ ,  $p<.0001$ ), ankle-brachial index ( $0.0\pm 0.1$  vs.  $0.2\pm 0.2$ ,  $p<.0001$ ) and shorter mean duration of  
239 the ischaemic symptoms (3.1 vs. 6.8 days,  $p=.0004$ ). Patients with ALI IIB also presented  
240 higher incidence of the cerebrovascular disease (32.2 vs. 17.9 %,  $p=.0543$ ) and the renal  
241 insufficiency (26.7 vs. 17.5 %,  $p=.0726$ ), but those differences were beyond the statistical  
242 significance (Table 3,4).

243 Subjects with ALI IIA presented higher frequency of smoking history (60.7 vs. 44.5  
244 %,  $p=.0425$ ), hyperlipidaemia (50.0 vs. 32.9 %,  $p=.0344$ ), claudication (39.3 vs. 6.2 %,  $p=.0344$ ),

245 p<.0001) and thrombosis (85.7 vs. 71.2 %, p=.0442+) as the cause of target occlusion (Table  
246 3, 4).

247

#### 248 ***Gender: Females vs. males***

249 Female gender was associated with higher mean age (75.1 vs. 67.9 years, p<.0001),  
250 higher incidence of hypertension (81.1 vs. 70.1 %, p=.0355), arrhythmias (34.8 vs. 19.0 %,  
251 p=.0017) and embolism (29.5 vs. 11.4 %, p<.0001) as the cause of target arterial occlusion.  
252 Additionally, the occlusion was more frequently located in the femoropopliteal arterial  
253 segment (79.5 vs. 68.5 %, p=.0296) and the deep femoral artery (15.2 vs. 6.5 %, p=.0142) in  
254 this subgroup. Male subgroup presented more frequent smoking history (67.4 vs. 36.4 %,  
255 p<.0001), renal insufficiency (27.7 vs. 17.4 %, p=.0429), tissue defect (18.5 vs. 9.8 %,  
256 p=.0375), thrombotic cause of the occlusion (88.6 vs. 70.5 %, p<.0001) and femoropopliteal  
257 bypass occlusion (28.8 vs. 14.4 %, p=.0027). A higher statistical trend in favour of  
258 claudication (33.2 vs. 23.5 %, p=.0785) was also detected in this subgroup (Table 7).

259

#### 260 ***Clinical presentation***

261 Comparison between ALI patients with immediately (IIB) and marginally (IIA)  
262 threatened extremities detected significantly shorter mean duration of the ischaemic  
263 symptoms (3.1 vs. 6.8 days, p=.0004). The incidence of tissue defects was higher in males  
264 (18.5 % vs. 9.8 %, p=.0375), SLI vs. ALI (22.8 vs 10.4 %, p=.0047), patients with  
265 thrombosis vs. embolism (17.2 vs. 5.0 %, p=.0151). The rest pain occurred more frequently  
266 in ALI group (83.7 % vs. 57.9 %, p<.0001), and in ALI IIB vs. ALI IIA (91.8 vs. 62.5 %,  
267 p<.0001). The claudication was detected in 53.5 % of subjects with SLI (vs. 15.3 % in ALI,  
268 p<.0001), 39.3 % of ALI IIA (vs. 6.2 % in ALI IIB, p<.0001) and in patients with thrombosis  
269 (32.4 %) vs. embolism (15.0 %, p=.0071) (Table 1,3,5,7).

270 DISCUSSION

271 Ischaemia severity, symptoms duration and their progression in time vary with the  
272 grade and dynamics of blood flow deterioration. Vessel anatomy before ALI attack, site and  
273 cause of acute arterial occlusion, collateral development, embolus fragmentation and its  
274 displacement to the peripheral branches, thrombosis progression, runoff quality and  
275 antithrombotic therapy are the factors influencing clinical presentation of ALI. Together with  
276 serious comorbidities, they affect periprocedural, early and long-term treatment outcomes,  
277 morbidity, mortality and amputation rates. Detailed angiography description and pre-  
278 treatment ABI data were often not presented in the study reports dedicated to surgical and/or  
279 endovascular therapy of ALI. Thus, the correlation of ischaemic symptoms and their duration  
280 with the limb hemodynamics and vascular anatomy is difficult or impossible from the  
281 literature.

282 In retrospective analysis of 160 ALI patients (symptoms duration 7 days or less, 13 %  
283 embolic and 87 % thrombotic occlusions, 75 % clinical category II) managed with 186  
284 intraarterial thrombolytic procedures, McNamara and colleagues<sup>12</sup> correlated angiographic  
285 patterns with clinical severity of ischemia. They based the angiographic categorization on the  
286 number of occluded arterial segments (common iliac, external iliac, common femoral,  
287 superficial femoral, popliteal, trifurcation, bypass grafts), presence of visible patent distal  
288 vessels, existence of patent collateral vessels, and the occurrence of stenoses involving inflow,  
289 collateral, or outflow vessels. Clinical category “viable“ (I) correlated with single-segment  
290 occlusion, patent collaterals and distal vessels. Patients requiring blood to flow through two  
291 contiguous collateral beds to supply distal vessels or with single occlusion combined with  
292 stenosis of the adjacent inflow, outflow or collateral vessel correlated with the clinical  
293 category “threatened“ (II). Occlusions of more than two segments with distal propagation that  
294 occluded the distal vascular bed correlated with the clinical category “irreversible“ (III).

295 Severity of ischemia and extent of the occlusion correlated with death and amputation rate at  
296 30 days.

297 In their study of 45 patients with embolic occlusions managed by thrombolysis, Huettl  
298 and Soulen<sup>13</sup> detected no patent calf vessels in 56 % of patients, one calf vessel was patent in  
299 22 %, two in 7 % and three in 16 % of patients before treatment. Those numbers are close to  
300 our data. Using thrombolysis and additional endovascular techniques for treatment of non-  
301 embolic ALI in 119 patients (72 % grafts, 68 % category I), Kashyap and associates<sup>14</sup>  
302 detected multisegmental thrombosis in 16 % and tibial thrombosis in 22 % of patients. Distal  
303 occlusions beyond the reach of the rheolytic catheter limited the treatment in 57 % of 86  
304 patients with ALI or SLI in the study of Kasirajan et al<sup>15</sup>. The need for distal thrombectomy  
305 and poor intra-operative runoff were detected among risk factors for amputation and death in  
306 107 patients with ALI undergoing infrainguinal bypass<sup>16</sup>. Also, any patent pedal outflow was  
307 a significant predictor for technical success in patients with ALI managed surgically (296 pts)  
308 or by endovascular technique (147 pts) in the study of Taha and associates<sup>17</sup>. Failed  
309 mechanical recanalization of the diffusely occluded infrapopliteal vascular bed influenced the  
310 need for thrombolytic therapy, the rate of major bleeding, treatment outcomes, amputation  
311 and mortality rates in patients with ALI and SLI<sup>8</sup>.

312 The greatest mean lesion lengths were reported in the studies of ALI and SLI patients  
313 with target occlusions located in the femoropopliteal bypass (32.1; 28.4 cm)<sup>18,19</sup>. In our series,  
314 the mean length of the target occlusion was 22.9 cm and 22.8 % of 316 patients suffered from  
315 occluded femoropopliteal bypass.

316 The comparison between patients with embolic vs. thrombotic cause of arterial  
317 occlusions, we documented higher age, higher frequency of female gender, cardiac disease,  
318 arrhythmias, ALI, ALI IIB, occlusions of femoropopliteal segment and/or profunda femoris in  
319 subjects with embolism. They also presented higher frequency of additional infrapopliteal

320 occlusion, lower number of patent tibial vessels and lower ABI before treatment. Thus,  
321 historical view that embolism produces more severe ischaemia than thrombosis was  
322 confirmed.

323 Thrombosis subgroup presented higher incidence of male gender, smoking history,  
324 subacute ischemia, acute ischemia IIA, claudication, tissue defect, femoropopliteal bypass and  
325 in-stent occlusions. Furthermore, these patients presented greater mean occlusion length,  
326 higher ABI and number of patent calf vessels. Aune and Trippestad<sup>20</sup> reported in their study  
327 of 272 patients managed by embolectomy (192 pts. with embolism) or bypass (80 pts. with  
328 thrombosis), a higher mean age, frequency of female gender and cardiac disease, together  
329 with shorter life expectancy in patients with embolism. Kuukasjarvi et al. in their study of 509  
330 ALI patients (without previous reconstructions) from National Vascular Registry<sup>21</sup> detected  
331 higher frequency of embolism in patients of age 75 or more years and smoking as a risk factor  
332 for acute thrombosis. The authors speculated that the worse prognosis (higher amputation  
333 rate, mortality rates and necessity for repeated interventions) of patients with acute thrombotic  
334 occlusion was associated with advanced atherosclerosis.

335 Higher age and frequency of hypertension, arrhythmias, embolism, occlusions of  
336 femoropopliteal segment and deep femoral artery were associated with female gender.  
337 Smoking history, renal insufficiency, tissue defects, thrombosis as a cause of the occlusion  
338 and femoropopliteal bypass occlusion were more frequent in patients of male gender.  
339 Additionally, we observed statistical trend toward more frequent claudication in the male  
340 group.

341 Similar results can be found in the literature. Braithwaite and colleagues<sup>22</sup> managed  
342 84 elderly patients (75-100 years) with ALI by surgery and/or thrombolysis. Percentage of  
343 females was 71.4 % in their series and female preponderance was greatest (84.8 %) in the  
344 subgroup selected for immediate embolectomy. Female predominance was detected also in

345 other studies: 57 % in subgroup with embolism<sup>18</sup> and 54 % of 23 268 ALI patients of the  
346 National Inpatient Sample (NIS)<sup>23</sup>. Kashyap and associates<sup>14</sup> reported increased risk of limb  
347 loss with the female gender in 119 ALI patients managed by thrombolysis. Mortality rate was  
348 6 % and dying patients were women only. Female gender as a risk associated with limb  
349 amputation was detected also by Kuoppala M and colleagues<sup>24</sup>. The NATALI study<sup>25</sup>  
350 described female gender as a risk factor for mortality and for all and major complications  
351 associated with thrombolytic treatment. On the other hand, Eliason JL et al.<sup>23</sup> reported  
352 decreased risk of amputation in women, in patients with embolectomy, percutaneous  
353 transluminal angioplasty and age less than 63 years in NIS patients. The authors did not detect  
354 the female preponderance or lower amputation risk in their single institution study (105  
355 patients).

356 ***CONCLUSION:***

357 Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented  
358 in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The  
359 value of ABI related to the number of occluded tibial arteries.

360 The most frequent locations of supratibial occlusions were femoropopliteal segment  
361 (73.1 %) and femoropopliteal bypass (22.8 %) without significant difference in clinical  
362 categories. Occlusion locations related to ALI (IIA+IIB) were the aortoiliac segment and/or  
363 profunda femoris. Also, more ALI subjects presented additional infrapopliteal occlusion  
364 (acute and/or subacute) and lower number of patent tibial arteries and lower ABI.

365 Anatomically, the important factor related to the ischaemia severity and symptoms  
366 duration was the status of infrapopliteal vascular bed. The number of patent or acutely,  
367 subacutely and chronically occluded tibial vessels related to individual clinical categories of  
368 ALI and SLI and to ABI. This suggests that tibial reperfusion can be essential for the salvage  
369 of threatened limb and should be always considered.

370 Patients with the most severe ischaemia and immediately threatened extremity (ALI  
371 IIB) presented shortest symptoms duration, higher frequency of rest pain, embolism, diabetes,  
372 additional acute infrapopliteal occlusion, lower number of patent tibial vessels and lower ABI  
373 in comparison with ALI IIA patients. More frequent diabetes can participate on higher  
374 number of occluded tibial vessels in this subgroup.

375 On the other hand, more patients with thrombosis, smoking history, hyperlipidemia,  
376 claudication, higher number of patent calf vessels and higher ABI were detected in ALI IIA  
377 subgroup.

378 In comparison with ALI group, the subjects with SLI presented more frequently the  
379 thrombosis as a cause of target occlusion, smoking history, claudication, tissue defects,  
380 shorter target occlusion, lower number of occluded tibial vessels and higher ABI.  
381 Furthermore, they presented younger age, less embolism and arrhythmias, less aortoiliac  
382 segment and deep femoral artery occlusions.

383 Embolism as a cause of the supratibial arterial occlusion was associated with higher  
384 age, female gender, cardiac disease, arrhythmias, ALI, ALI IIB, femoropopliteal segment and  
385 deep femoral artery occlusions, infrapopliteal occlusions, lower ABI and number of patent  
386 calf vessels. Higher ischaemia severity in subjects with embolism was not associated only  
387 with the fact that embolus suddenly occluded healthy supratibial artery but also with higher  
388 frequency of additional infrapopliteal occlusion, profunda femoris occlusion and the higher  
389 number of occluded tibial vessels. The data confirmed a historical view that the most severe  
390 ischemia occurs with the embolism.

391 Thrombosis was associated with smoking history, SLI, ALI IIA, claudication, tissue  
392 defects, longer target lesion, femoropopliteal bypass occlusion, in-stent occlusion, higher ABI  
393 and number of patent calf vessels.

394 Patients of female gender presented higher age, higher frequency of hypertension,  
395 arrhythmias, embolism, femoropopliteal and profunda femoris occlusions. Male group  
396 manifested a higher frequency of smoking history, renal insufficiency, tissue defect,  
397 thrombosis and femoropopliteal bypass occlusion.

398 Grouping the patients categorized in different clinical categories of ALI and SLI can  
399 affect the treatment outcomes.

400

#### 401 REFERENCES


- 402 1. Norgren L, Hiatt WR, Dormandy JA et al. Inter-society consensus for the management of  
403 peripheral arterial diseases (TASC II). *Eur J Vasc Endovasc Surg* 2007;33, suppl 1:S1-S75.
- 404 2. Rutherford RB, Baker JD, Ernst C et al. Recommended standards for reports dealing with  
405 lower extremity ischemia: Revised version. *J Vasc Surg* 1997;26:517-538.
- 406 3. Patel N, Sacks D, Patel RI et al. SCVIR reporting standards for the treatment of acute limb  
407 ischemia with use of transluminal removal of arterial thrombus. *J Vasc Interv Radiol*  
408 2001;12:559-570.
- 409 4. Karnabatidis D, Spiliopoulos S, Tsetis D, Siablis D. Quality improvement guidelines for  
410 percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for  
411 acute lower-limb ischemia. *Cardiovasc Intervent Radiol* 2011;34:1123-1136.
- 412 5. Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. *Surgery*  
413 1998;124:336-342.
- 414 6. Henke PK. Contemporary management of acute limb ischemia: factors associated with  
415 amputation and in-hospital mortality. *Semin Vasc Surg* 2009;22:34-40.
- 416 7. Dosluoglu HH, Harris LM. Endovascular management of subacute lower extremity  
417 ischemia. *Semin Vasc Surg* 2008;21:167-179.
- 418 8. Bulvas M, Sommerová Z, Vaněk I, Weiss J. Prospective single-arm trial of endovascular  
419 mechanical debulking as initial therapy in patients with acute and subacute lower limb  
420 ischemia: one-year outcomes. *J Endovasc Ther* 2019;26:291-301.
- 421 9. Hirsch AT, Haskal ZJ, Hertzler NR, et al. ACC/AHA 2005 guidelines for the management  
422 of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal  
423 aortic): executive summary. A collaborative report from the American Association for  
424 Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and  
425 Interventions, Society for Vascular Medicine and Biology, Society of Interventional  
426 Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to  
427 Develop Guidelines for the Management of Patients With Peripheral Arterial Disease).  
428 Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation;  
429 National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-  
430 Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol* 2006;47:1239-  
431 1312.

432



- 433 10. Tendera M, Aboyans V, Bartelink ML, et al. ESC guidelines on the diagnosis and  
434 treatment of peripheral artery diseases: document covering atherosclerotic disease of  
435 extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The  
436 Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European  
437 Society of Cardiology (ESC). *Eur Heart J* 2011;32:2851–2906.  
438
- 439 11. O’Connell JB, Quiñones-Baldrich WJ. Proper evaluation and management of acute  
440 embolic versus thrombotic limb ischemia. *Semin Vasc Surg* 2009;22:10-16.
- 441 12. McNamara TO, Gardner KR, Bomberger RA, Greaser LE. Clinical and angiographic  
442 selection factors for thrombolysis as initial therapy for acute lower limb ischemia. *J Vasc*  
443 *Interv Radiol* 1995;6(suppl):36S-47S.  
444
- 445 13. Huettl EA, Soulen MC. Thrombolysis of lower extremity embolic occlusions: a study of  
446 the results of the Star Registry. *Radiology* 1995;197:141-145.  
447
- 448 14. Kashyap VS, Gilani R, Bena JF, Bannazadeh M, Sarac TP. Endovascular therapy for  
449 acute limb ischemia. *J Vasc Surg* 2011;53:340-46.  
450
- 451 15. Kasirajan K, Gray B, Beavers FP, Clair DG, Greenberg R, Mascha E, Ouriel K. Rheolytic  
452 thrombectomy in the management of acute and subacute limb-threatening ischemia.  
453 *J Vasc Interv Radiol* 2001; 12:413–421.  
454
- 455 16. Marqués de Marino P, Martínez López I, Revuelta Suero S et al. Results of infrainguinal  
456 bypass in acute limb ischaemia. *Eur J Vasc Endovasc Surg* 2016;51:824-30.  
457
- 458 17. Taha AG, Byrne RM, Avgerinos ED, Marone LK et al. Comparative effectiveness of  
459 endovascular versus surgical revascularization for acute lower extremity ischemia *J Vasc Surg*  
460 2015;61:147-54.  
461
- 462 18. Hundt W, Kalinowski M, Stamm AC, Portig I, Swaid Z, Dietz C, Geks J, Burbelko M.  
463 Combined treatment of subacute and acute synthetic and venous bypass-graft occlusions with  
464 percutaneous mechanical thrombectomy and thrombolysis. *Eur J Radiol* 2013;82:e807– e815.  
465 doi: 10.1016/j.ejrad.2013.08.016
- 466 19. Wissgott C, Kamusella P, Andresen R. Recanalization of acute and subacute venous and  
467 synthetic bypass-graft occlusions with a mechanical rotational catheter. *Cardiovasc Intervent*  
468 *Radiol* 2013;36:936–942.  
469
- 470 20. Aune S, Trippstad A. Operative mortality and long-term survival of patients operated on  
471 for acute lower limb ischaemia. *Eur J Vasc Endovasc Surg* 1998;15:143-146.  
472
- 473 21. Kuukasjarvi P, Salenius J.P and the Finnvasc study group. Perioperative outcome of acute  
474 lower limb ischaemia on the basis of the National Vascular Registry. *Eur J Vasc Surg*  
475 1994;8:578-583.  
476
- 477 22. Braithwaite BD, Davies B, Birch PA, Heather BP, Earnshaw JJ. Management of acute leg  
478 ischaemia in the elderly. *Brit J Surg* 1998;85:217-220.  
479


- 480 23. Eliason JL, Wainess RM, Proctor MC, Dimick JB, Cowan JA et al. A National and single  
481 institutional experience in the contemporary treatment of acute lower extremity ischemia. *Ann*  
482 *Surg* 2003;238:382-390.
- 483 24. Kuoppala M, Franzén S, Lindblad B, Acosta S. Long-term prognostic factors after  
484 thrombolysis for lower limb ischemia. *J Vasc Surg* 2008;47:1243-1250.
- 485  
486 25. Earnshaw JJ, Whitman B, Foy C for the Thrombolysis Study Group. National Audit of  
487 Thrombolysis for Acute Leg Ischemia (NATALI): Clinical factors associated with early  
488 outcome. *J Vasc Surg* 2004;39:1018-25.  
489



| Characteristics                                       | Summary Statistics           | All Subjects       | Sub-Acute Ischemia | Acute Ischemia     | p-value |
|---|------------------------------|--------------------|--------------------|--------------------|---------|
| <b>Number of patent calf vessels before treatment</b> | <b>n</b><br><b>Mean ± SD</b> | 316<br>0.9 ± 1.1   | 114<br>1.3 ± 1.2   | 202<br>0.7 ± 1.0   | <.0001  |
| <b>Patients with no patent tibial vessels</b>         | <b>% (n/N)</b>               | 51.9%<br>(164/316) | 33.3%<br>(38/114)  | 62.4%<br>(126/202) | 0.0001  |
| <b>Patients with 1 patent tibial vessel</b>           | <b>% (n/N)</b>               | 17.7%<br>(56/316)  | 22.8%<br>(26/114)  | 14.9%<br>(30/202)  | 0.0914  |
| <b>Patients with 2 patent tibial vessels</b>          | <b>% (n/N)</b>               | 16.5%<br>(52/316)  | 21.9%<br>(25/114)  | 13.4%<br>(27/202)  | 0.0581  |
| <b>Patients with 3 patent tibial vessels</b>          | <b>% (n/N)</b>               | 13.9%<br>(44/316)  | 21.9%<br>(25/114)  | 9.4% (19/202)      | 0.0036  |


**Fig. 1.** ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD - standard deviation, vss-vessel(s)

## ABI in Subacute and Acute Ischemia




| Characteristics             | Summary Statistics           | All Subjects     | Sub-Acute Ischemia | Acute Ischemia   | p-value |
|-----------------------------|------------------------------|------------------|--------------------|------------------|---------|
| <b>ABI before treatment</b> | <b>n</b><br><b>Mean ± SD</b> | 309<br>0.1 ± 0.2 | 108<br>0.2 ± 0.2   | 201<br>0.1 ± 0.1 | <.0001  |
| <b>ABI 0-0.1</b>            | <b>% (n/N)</b>               | 57% (176/309)    | 31.4% (34/108)     | 71.2% (143/201)  | <.0001  |
| <b>ABI 0.11-0.2</b>         | <b>% (n/N)</b>               | 8.7% (27/309)    | 7.6% (8/108)       | 9.0% (18/201)    | 0.8302  |
| <b>ABI 0.21-0.3</b>         | <b>% (n/N)</b>               | 14.2% (44/309)   | 25.7% (28/108)     | 8.5% (17/201)    | 0.0001  |
| <b>ABI 0.31-0.4</b>         | <b>% (n/N)</b>               | 13.9% (43/309)   | 23.8% (26/108)     | 8.0% (16/201)    | 0.0002  |
| <b>ABI 0.41-0.5</b>         | <b>% (n/N)</b>               | 4.5% (14/309)    | 8.6% (9/108)       | 2.5% (5/201)     | 0.0236  |
| <b>ABI 0.51-0.6</b>         | <b>% (n/N)</b>               | 1.3% (4/309)     | 2.8% (3/108)       | 0.5% (1/201)     | 0.1245  |
| <b>ABI 0.61-0.7</b>         | <b>% (n/N)</b>               | 0.3% (1/309)     | 0% (0/108)         | 0.5% (1/201)     |         |

**Fig. 2.** Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 – 0.5), SLI is more frequent.



| Breakdown Table of Descriptive Statistics (tibial vessels patent, ABI) |               |           |            |                 |                 |
|--|---------------|-----------|------------|-----------------|-----------------|
| <b>Welch ANOVA test (p&lt;0.001)</b>                                   |               |           |            |                 |                 |
| SLI tibial vessels patent  | ABI SLI Means | ABI SLI N | ABI SLI SD | ABI SLI Minimum | ABI SLI Maximum |
| 0  | 0.139         | 37        | 0.160      | 0               | 0.420           |
| 1  | 0.214         | 21        | 0.129      | 0               | 0.450           |
| 2  | 0.244         | 25        | 0.156      | 0               | 0.460           |
| 3  | 0.346         | 24        | 0.150      | 0               | 0.600           |
| All Groups   | 0.229         | 107       | 0.168      | 0               | 0.600           |

**Fig. 3.** The number of patent tibial vessels significantly ( $p<.001$ ) correlates to ABI in SLI patients .



| Breakdown Table of Descriptive Statistics (tibial vessels patent, ABI) |               |           |            |                 |                 |
|--|---------------|-----------|------------|-----------------|-----------------|
| <b>Welch ANOVA test (p&lt;0.001)</b>                                   |               |           |            |                 |                 |
| ALI tibial vessels patent  | ABI ALI Means | ABI ALI N | ABI ALI SD | ABI ALI Minimum | ABI ALI Maximum |
| 0  | 0.032         | 125       | 0.090      | 0               | 0.460           |
| 1  | 0.150         | 30        | 0.165      | 0               | 0.460           |
| 2  | 0.151         | 27        | 0.173      | 0               | 0.560           |
| 3  | 0.149         | 19        | 0.176      | 0               | 0.620           |
| All Groups   | 0.081         | 201       | 0.140      | 0               | 0.620           |

**Fig. 4.** Also in ALI patients, the number of patent tibial vessels significantly ( $p<0.001$ ) correlates to ABI.

## LEGENDS

Fig. 1. ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD - standard deviation, vss-vessel(s)

Fig. 2. Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 – 0.5), SLI is more frequent.

Fig. 3. The number of patent tibial vessels significantly ( $p<.001$ ) correlates to ABI in SLI patients.

Fig. 4. Also in ALI patients, the number of patent tibial vessels significantly ( $p<.001$ ) correlates to ABI.

Table 1. Demography, concomitant disease, ischemia classification and symptoms: SLI vs. ALI

Table 2. Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI

Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB

Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB

Table 5. Demographics, concomitant disease, ischemia classification and symptoms: thrombosis vs. embolism

Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism

Table 7. Age, concomitant disease, symptoms, ischemia classification, occlusion length and location: female vs. male gender

Table 1. Demography, concomitant disease, ischaemia classification and symptoms: SLI vs.

ALI

| Characteristics                   | Summary Statistics                                     | All Subjects                             | Sub-Acute Ischemia                       | Acute Ischemia                           | p-value |
|-----------------------------------|--|--|--|--|---------|
| Age (years)                       | <b>n</b><br>Mean ± SD<br><b>Median</b><br><b>Range</b> | 316<br>70.9 ± 12.0<br>71.0<br>23.0, 96.0 | 114<br>67.9 ± 10.9<br>67.0<br>31.0, 94.0 | 202<br>72.6 ± 12.2<br>73.0<br>23.0, 96.0 | 0.0005  |
| Male                              | % (n/N)  | 58.2% (184/316)                          | 61.4% (70/114)                           | 56.4% (114/202)                          | 0.4079  |
| Diabetes                          | % (n/N)  | 30.7% (97/316)                           | 28.1% (32/114)                           | 32.2% (65/202)                           | 0.5256  |
| Smoking history                   | % (n/N)  | 54.4% (172/316)                          | 64.0% (73/114)                           | 49.0% (99/202)                           | 0.0134  |
| Hyperlipidaemia                   | % (n/N)  | 38.9% (123/316)                          | 41.2% (47/114)                           | 37.6% (76/202)                           | 0.5496  |
| Hypertension                      | % (n/N)  | 74.7% (236/316)                          | 73.7% (84/114)                           | 75.2% (152/202)                          | 0.7884  |
| Cardiac disease                   | % (n/N)  | 42.1% (133/316)                          | 35.1% (40/114)                           | 46.0% (93/202)                           | 0.0749  |
| Arrhythmias                       | % (n/N)  | 25.6% (81/316)                           | 16.7% (19/114)                           | 30.7% (62/202)                           | 0.0071  |
| Cerebrovascular disease           | % (n/N)  | 25.0% (79/316)                           | 19.3% (22/114)                           | 28.2% (57/202)                           | 0.0809  |
| Malignant disease                 | % (n/N)  | 7.3% (23/316)                            | 7.9% (9/114)                             | 6.9% (14/202)                            | 0.8226  |
| Renal insufficiency               | % (n/N)  | 23.4 % (74/316)                          | 17.5 % (20/114)                          | 26.7 % (54/202)                          | 0.0726  |
| Acute limb ischaemia category IIA | % (n/N)  | 17.7% (56/316)                           |  | 27.7% (56/202)                           |         |
| Acute limb ischaemia category IIB | % (n/N)  | 46.2% (146/316)                          |  | 72.3% (146/202)                          |         |
| Subacute limb ischaemia           | % (n/N)  | 36.1% (114/316)                          | 100% (114/114)                           |  |         |
| Symptoms duration                 | days   | 70.9±12.0                                | 44.3±27.3                                | 4.13±4.47                                | <.0001  |
| Claudication                      | % (n/N)  | 29.1% (92/316)                           | 53.5% (61/114)                           | 15.3% (31/202)                           | <.0001  |
| Rest pain                         | % (n/N)  | 74.4% (235/316)                          | 57.9% (66/114)                           | 83.7% (169/202)                          | <.0001  |
| Tissue defect                     | % (n/N)  | 14.9% (47/316)                           | 22.8% (26/114)                           | 10.4% (21/202)                           | 0.0047  |



Table 2 Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI

| Characteristics                                       | Summary Statistics  | All Subjects                                 | Sub-Acute Ischemia                           | Acute Ischemia                               | p-value |
|---|---|--|--|--|---------|
| <b>Target occlusion length (mm)</b>                   | <b>n</b><br><b>Mean ± SD</b><br><b>Median</b><br><b>Range</b> | 316<br>229.2 ± 148.1<br>200.0<br>15.0, 650.0 | 114<br>202.0 ± 136.7<br>150.0<br>15.0, 650.0 | 202<br>244.6 ± 152.4<br>200.0<br>20.0, 590.0 | 0.0159  |
| <b>Target occlusion cause: Embolism</b>               | <b>% (n/N)</b>  | 19.0% (60/316)                               | 8.8% (10/114)                                | 24.8% (50/202)                               | 0.0005  |
| <b>Target occlusion cause: Thrombosis</b>             | <b>% (n/N)</b>  | 81.0% (256/316)                              | 91.2% (104/114)                              | 75.2% (152/202)                              | 0.0005  |
| <b>Aortoiliac segment occlusion</b>                   | <b>% (n/N)</b>  | 11.1% (35/316)                               | 6.1% (7/114)                                 | 13.9% (28/202)                               | 0.0401  |
| <b>Femoropopliteal segment occlusion</b>              | <b>% (n/N)</b>  | 73.1% (231/316)                              | 78.9% (90/114)                               | 69.8% (141/202)                              | 0.0868  |
| <b>Femoropopliteal bypass occlusion</b>               | <b>% (n/N)</b>  | 22.8% (72/316)                               | 17.5% (20/114)                               | 25.7% (52/202)                               | 0.1241  |
| <b>Femoro-femoral cross bypass occlusion</b>          | <b>% (n/N)</b>  | 0.6% (2/316)                                 | 0  | 1.0% (2/202)                                 | 0.5373  |
| <b>Leg of bifurcation stentgraft occlusion</b>        | <b>% (n/N)</b>  | 0.3% (1/316)                                 | 0  | 0.5% (1/202)                                 | 1.0000  |
| <b>Ileofemoral bypass occlusion</b>                   | <b>% (n/N)</b>  | 0.3% (1/316)                                 | 0.9% (1/114)                                 | 0  | 0.3608  |
| <b>Deep femoral artery occlusion</b>                  | <b>% (n/N)</b>  | 10.1% (32/316)                               | 5.3% (6/114)                                 | 12.9% (26/202)                               | 0.0332  |
| <b>In-stent occlusion</b>                             | <b>% (n/N)</b>  | 23.4% (74/316)                               | 21.9% (24/114)                               | 24.3% (49/202)                               | 0.6800  |
| <b>Additional infrapopliteal occlusion</b>            | <b>% (n/N)</b>  | 61.7% (195/316)                              | 50.0% (57/114)                               | 68.3% (138/202)                              | 0.0017  |
| <b>Number of patent calf vessels before treatment</b> | <b>n</b><br><b>Mean ± SD</b><br><b>Median</b><br><b>Range</b> | 316<br>0.9 ± 1.1<br>0.0<br>0.0, 4.0          | 114<br>1.3 ± 1.2<br>1.0<br>0.0, 3.0          | 202<br>0.7 ± 1.0<br>0.0<br>0.0, 4.0          | <.0001  |
| <b>ABI before treatment</b>                           | <b>n</b><br><b>Mean ± SD</b><br><b>Median</b><br><b>Range</b> | 309<br>0.1 ± 0.2<br>0.0<br>0.0, 0.6          | 108<br>0.2 ± 0.2<br>0.3<br>0.0, 0.6          | 201<br>0.1 ± 0.1<br>0.0<br>0.0, 0.6          | <.0001  |

Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB.

| Characteristics                    | Summary Statistics | All ALI Subjects | ALI IIA        | ALI IIB         | p-value |
|------------------------------------|--------------------|------------------|----------------|-----------------|---------|
| Age (years)                        | <b>n</b>           | 202              | 56             | 146             | 0.2113  |
|                                    | <b>Mean ± SD</b>   | 72.6 ± 12.2      | 70.8 ± 12.9    | 73.2 ± 11.9     |         |
|                                    | <b>Median</b>      | 73.0             | 73.0           | 74.0            |         |
|                                    | <b>Range</b>       | 23.0, 96.0       | 23.0, 96.0     | 43.0, 96.0      |         |
| Male                               | % (n/N)            | 56.4% (114/202)  | 62.5% (35/56)  | 54.1% (79/146)  | 0.4079  |
| Diabetes                           | % (n/N)            | 32.2% (65/202)   | 21.4% (12/56)  | 36.3% (53/146)  | 0.0452  |
| Smoking history                    | % (n/N)            | 49.0% (99/202)   | 60.7% (34/56)  | 44.5% (65/146)  | 0.0425  |
| Hyperlipidaemia                    | % (n/N)            | 37.6% (76/202)   | 50.0% (28/56)  | 32.9% (48/146)  | 0.0344  |
| Hypertension                       | % (n/N)            | 75.2% (152/202)  | 71.4% (40/56)  | 76.7% (112/146) | 0.4685  |
| Cardiac disease                    | % (n/N)            | 46.0% (93/202)   | 41.1% (23/56)  | 47.9% (70/146)  | 0.4319  |
| Arrhythmias                        | % (n/N)            | 30.7% (62/202)   | 28.6% (16/56)  | 31.5% (46/146)  | 0.7357  |
| Cerebrovascular disease            | % (n/N)            | 28.2% (57/202)   | 17.9% (10/56)  | 32.2% (47/146)  | 0.0543  |
| Malignant disease                  | % (n/N)            | 6.9% (14/202)    | 5.4% (3/56)    | 7.5% (11/146)   | 0.7615  |
| Renal insufficiency                | % (n/N)            | 23.4% (74/316)   | 17.5% (20/114) | 26.7% (54/202)  | 0.0726  |
| Symptoms duration (days)           | <b>n</b>           | 202              | 56             | 146             | 0.0004  |
|                                    | <b>Mean ± SD</b>   | 4.1±4.5          | 6.8±5.3        | 3.1±3.6         |         |
|                                    | <b>Median</b>      | 2.0              | 6.5            | 2.0             |         |
|                                    | <b>Range</b>       | 0.04, 14.0       | 0.08, 14.0     | 0.04, 14.0      |         |
| Claudication                       | % (n/N)            | 15.3% (31/202)   | 39.3% (22/56)  | 6.2% (9/146)    | <.0001  |
|                                    | % (n/N)            |                  |                |                 |         |
| Rest pain                          | % (n/N)            | 83.7% (169/202)  | 62.5% (35/56)  | 91.8% (134/146) | <.0001  |
| Tissue defect                      | % (n/N)            | 10.4% (21/202)   | 10.7% (6/56)   | 10.3% (15/146)  | 1.000   |
| Target occlusion cause: Embolism   | % (n/N)            | 24.8% (50/202)   | 14.3% (8/56)   | 28.8% (42/146)  | 0.0442  |
| Target occlusion cause: Thrombosis | % (n/N)            | 75.2% (152/202)  | 85.7% (48/56)  | 71.2% (104/146) | 0.0442  |

Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB

| Characteristics                             | Summary Statistics  | All Subjects         | ALI IIA              | ALI IIB              | p-value |
|---|---------------------|----------------------|----------------------|----------------------|---------|
| Target occlusion length (mm)                | <b>n</b>            | 202                  | 56                   | 146                  | 0.0938  |
|   | <b>Mean ± SD</b>    | 244.6 ± 152.4        | 215.5 ± 150.2        | 255.7 ± 152.3        |         |
|   | <b>Median Range</b> | 200.0<br>20.0, 590.0 | 150.0<br>20.0, 550.0 | 220.0 20.0,<br>590.0 |         |
| Aortoiliac segment occlusion                | % (n/N)             | 13.9 %<br>(28/202)   | 14.3 %<br>(8/56)     | 13.7 %<br>(20/146)   | 1.000   |
| Femoropopliteal segment occlusion           | % (n/N)             | 69.8%<br>(141/202)   | 69.6%<br>(39/56)     | 69.9%<br>(102/146)   | 1.000   |
| Femoropopliteal bypass                      | % (n/N)             | 25.7 %<br>(52/202)   | 25.0 %<br>(14/56)    | 26.0 %<br>(38/146)   | 1.000   |
| Leg of bifurcation stentgraft occlusion     | % (n/N)             | 0.5% (1/202)         | 1.8% (1/56)          | 0.5% (1/202)         | 0.2772  |
| Ileofemoral bypass occlusion                | % (n/N)             | 25.7% (52/202)       | 25.0% (14/56)        | 26.0% (38/146)       | 1.000   |
| Deep femoral artery occlusion               | % (n/N)             | 12.9% (26/202)       | 5.4% (3/56)          | 15.8% (23/146)       | 0.0597  |
| In-stent occlusion                          | % (n/N)             | 24.3% (49/202)       | 33.9% (19/56)        | 20.5% (30/146)       | 0.0657  |
| Additional infrapopliteal occlusion         | % (n/N)             | 68.3% (138/202)      | 57.1% (32/56)        | 72.6% (106/146)      | 0.0427  |
| No. of patent calf vessels before treatment | <b>n</b>            | 202                  | 56                   | 146                  | <.0001  |
|   | <b>Mean ± std</b>   | 0.7± 1.0             | 1.4 ± 1.1            | 0.4± 0.9             |         |
|   | <b>Median Range</b> | 0.0<br>0.0, 4.0      | 1.0<br>0.0, 3.0      | 0.0<br>0.0, 4.0      |         |
| ABI before treatment                        | <b>n</b>            | 201                  | 55                   | 146                  | <.0001  |
|   | <b>Mean ± SD</b>    | 0.1 ± 0.1            | 0.2 ± 0.2            | 0.0 ± 0.1            |         |
|   | <b>Median Range</b> | 0.0<br>0.0, 0.6      | 0.2<br>0.0, 0.6      | 0.0<br>0.0, 0.4      |         |

Table 5. Demographics, concomitant disease, ischaemia classification and symptoms: thrombosis vs. embolism

| Characteristics           | Summary Statistics | All Subjects    | Thrombosis      | Embolism      | p-value |
|---------------------------|--------------------|-----------------|-----------------|---------------|---------|
| Age (years)               | <b>n</b>           | 316             | 256             | 60            | 0.0054  |
|                           | <b>Mean ± SD</b>   | 70.9 ± 12.0     | 70.2 ± 11.3     | 73.7 ± 14.2   |         |
|                           | <b>Median</b>      | 71.0            | 70.0            | 76.0          |         |
|                           | <b>Range</b>       | 23.0, 96.0      | 43.0, 96.0      | 23.0, 94.0    |         |
| Male                      | % (n/N)            | 58.2% (184/316) | 63.7% (163/256) | 35.0% (21/60) | <.0001  |
| Female                    | % (n/N)            | 41.8% (132/316) | 36.3% (93/256)  | 65.0% (39/60) | <.0001  |
| Diabetes                  | % (n/N)            | 30.7% (97/316)  | 30.1% (77/256)  | 33.3% (20/60) | 0.6425  |
| Smoking history           | % (n/N)            | 54.4% (172/316) | 59.8% (153/256) | 31.7% (19/60) | <.0001  |
| Hyperlipidaemia           | % (n/N)            | 38.9% (123/316) | 39.5% (101/256) | 36.7% (22/60) | 0.7692  |
| Hypertension              | % (n/N)            | 74.7% (236/316) | 74.6% (191/256) | 75.0% (45/60) | 1.0000  |
| Cardiac disease           | % (n/N)            | 42.1% (133/316) | 37.5% (96/256)  | 61.7% (37/60) | 0.0008  |
| Arrhythmias               | % (n/N)            | 25.6% (81/316)  | 19.5% (50/256)  | 51.7% (31/60) | <.0001  |
| Cerebrovascular disease   | % (n/N)            | 25.0% (79/316)  | 26.6% (68/256)  | 18.3% (11/60) | 0.2458  |
| Malignant disease         | % (n/N)            | 7.3% (23/316)   | 7.8% (20/256)   | 5.0% (3/60)   | 0.5874  |
| Renal insufficiency       | % (n/N)            | 23.4% (74/316)  | 23.8% (61/256)  | 21.7% (13/60) | 0.8657  |
| Subacute ischaemia        | % (n/N)            | 36.1% (114/316) | 40.6% (104/256) | 16.7% (10/60) | 0.0005  |
| Acute ischaemia           | % (n/N)            | 63.9% (202/316) | 59.4% (152/256) | 83.3% (50/60) | 0.0005  |
| Acute ischaemia class IIA | % (n/N)            | 27.7% (56/202)  | 31.6% (48/152)  | 16.0% (8/50)  | 0.0442  |
| Acute ischaemia class IIB | % (n/N)            | 72.3% (146/202) | 68.4% (104/152) | 84.0% (42/50) | 0.0442  |
| Claudication              | % (n/N)            | 29.1% (92/316)  | 32.4% (83/256)  | 15.0% (9/60)  | 0.0071  |
| Critical limb ischemia    | % (n/N)            | 23.4% (74/316)  | 26.6% (68/256)  | 10.0% (6/60)  | 0.0062  |
| Rest pain                 | % (n/N)            | 74.4% (235/316) | 73.8% (189/256) | 76.7% (46/60) | 0.7436  |
| Tissue defect             | % (n/N)            | 14.9% (47/316)  | 17.2% (44/256)  | 5.0% (3/60)   | 0.0151  |

Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism

| Characteristics                             | Summary Statistics | All Subjects    | Thrombosis      | Embolism      | p-value |
|---|--------------------|-----------------|-----------------|---------------|---------|
| Target lesion length (mm)                   | <b>n</b>           | 316             | 256             | 60            | <.0001  |
|   | <b>Mean ± SD</b>   | 229.2 ± 148.1   | 246.6 ± 150.4   | 155.0 ± 111.7 |         |
|   | <b>Median</b>      | 200.0           | 220.0           | 125.0         |         |
|   | <b>Range</b>       | 15.0, 650.0     | 15.0, 650.0     | 20.0, 480.0   |         |
| Aortoiliac segment                          | % (n/N)            | 11.1% (35/316)  | 10.2% (26/256)  | 15.0% (9/60)  | 0.3588  |
| Femoropopl segment                          | % (n/N)            | 73.1% (231/316) | 68.0% (174/256) | 95.0% (57/60) | <.0001  |
| Femoropopl bypass                           | % (n/N)            | 22.8% (72/316)  | 27.7% (71/256)  | 1.7% (1/60)   | <.0001  |
| Femo-femoral cross bypass                   | % (n/N)            | 0.6% (2/316)    | 0.8% (2/256)    |               |         |
| Leg of bifurcation stentgraft               | % (n/N)            | 0.3% (1/316)    | 0.4% (1/256)    |               |         |
| Ileofemoral bypass                          | % (n/N)            | 0.3% (1/316)    | 0.4% (1/256)    |               |         |
| Deep femoral artery                         | % (n/N)            | 10.1% (32/316)  | 7.0% (18/256)   | 23.3% (14/60) | 0.0006  |
| In-stent occlusion                          | % (n/N)            | 23.4% (74/316)  | 27.7% (71/256)  | 5.0% (3/60)   | <.0001  |
| Additional infrapopliteal occlusion         | % (n/N)            | 61.7% (195/316) | 59.0% (151/256) | 73.3% (44/60) | 0.0403  |
| No. of patent calf vessels before treatment | <b>n</b>           | 316             | 256             | 60            | <.0001  |
|   | <b>Mean ± SD</b>   | 0.9 ± 1.1       | 1.0 ± 1.1       | 0.4 ± 0.9     |         |
|   | <b>Median</b>      | 0.0             | 1.0             | 0.0           |         |
|   | <b>Range</b>       | 0.0, 4.0        | 0.0, 3.0        | 0.0, 4.0      |         |
| ABI before treatment                        | <b>n</b>           | 309             | 250             | 59            | 0.0016  |
|   | <b>Mean ± SD</b>   | 0.1 ± 0.2       | 0.14 ± 0.17     | 0.07 ± 0.14   |         |
|   | <b>Median</b>      | 0.0             | 0.0             | 0.0           |         |
|   | <b>Range</b>       | 0.0, 0.6        | 0.0, 0.6        | 0.0, 0.5      |         |

Table 7. Age, concomitant disease, symptoms, ischaemia classification, occlusion length and location: female vs. male gender

| Characteristics                     | Summary Statistics | All Subjects    | Female          | Male            | p-value |
|-------------------------------------|--------------------|-----------------|-----------------|-----------------|---------|
| Age (years)                         | n                  | 316             | 132             | 184             | <.0001  |
|                                     | Mean ± SD          | 70.9 ± 12.0     | 75.1 ± 11.4     | 67.9 ± 11.5     |         |
|                                     | Median             | 71.0            | 76.5            | 67.5            |         |
|                                     | Range              | 23.0, 96.0      | 23.0, 96.0      | 31.0, 94.0      |         |
| Diabetes                            | % (n/N)            | 30.7% (97/316)  | 33.3% (44/132)  | 28.8% (53/184)  | 0.3903  |
| Smoking history                     | % (n/N)            | 54.4% (172/316) | 36.4% (48/132)  | 67.4% (124/184) | <.0001  |
| Hyperlipidaemia                     | % (n/N)            | 38.9% (123/316) | 41.7% (55/132)  | 37.0% (68/184)  | 0.4147  |
| Hypertension                        | % (n/N)            | 74.7% (236/316) | 81.1% (107/132) | 70.1% (129/184) | 0.0355  |
| Cardiac disease                     | % (n/N)            | 42.1% (133/316) | 42.4% (56/132)  | 41.8% (77/184)  | 1.0000  |
| Arrhythmias                         | % (n/N)            | 25.6% (81/316)  | 34.8% (46/132)  | 19.0% (35/184)  | 0.0017  |
| Cerebrovascular disease             | % (n/N)            | 25.0% (79/316)  | 25.0% (33/132)  | 25.0% (46/184)  | 1.0000  |
| Malignant disease                   | % (n/N)            | 7.3% (23/316)   | 6.8% (9/132)    | 7.6% (14/184)   | 0.8301  |
| Renal insufficiency                 | % (n/N)            | 23.4% (74/316)  | 17.4% (23/132)  | 27.7% (51/184)  | 0.0429  |
| Acute limb ischaemia category IIA   | % (n/N)            | 27.7% (56/202)  | 23.9% (21/88)   | 30.7% (35/114)  | 0.3420  |
| Acute limb ischaemia category IIB   | % (n/N)            | 72.3% (146/202) | 76.1% (67/88)   | 69.3% (79/114)  | 0.3420  |
| Claudication                        | % (n/N)            | 29.1% (92/316)  | 23.5% (31/132)  | 33.2% (61/184)  | 0.0785  |
| Critical limb ischaemia             | % (n/N)            | 23.4% (74/316)  | 21.2% (28/132)  | 25.0% (46/184)  | 0.5011  |
| Rest pain                           | % (n/N)            | 74.4% (235/316) | 78.8% (104/132) | 71.2% (131/184) | 0.1509  |
| Tissue defect                       | % (n/N)            | 14.9% (47/316)  | 9.8% (13/132)   | 18.5% (34/184)  | 0.0375  |
| Target occlusion cause: Embolism    | % (n/N)            | 19.0% (60/316)  | 29.5% (39/132)  | 11.4% (21/184)  | <.0001  |
| Target occlusion cause: Thrombosis  | % (n/N)            | 81.0% (256/316) | 70.5% (93/132)  | 88.6% (163/184) | <.0001  |
| Target occlusion length (mm)        | n                  | 316             | 132             | 184             | 0.5290  |
|                                     | Mean ± SD          | 229.2 ± 148.1   | 221.0 ± 142.1   | 235.1 ± 152.5   |         |
|                                     | Median             | 200.0           | 200.0           | 200.0           |         |
|                                     | Range              | 15.0, 650.0     | 20.0, 590.0     | 15.0, 650.0     |         |
| Aortoiliac segment                  | % (n/N)            | 11.1% (35/316)  | 14.4% (19/132)  | 8.7% (16/184)   | 0.1453  |
| Femoropopliteal segment             | % (n/N)            | 73.1% (231/316) | 79.5% (105/132) | 68.5% (126/184) | 0.0296  |
| Femoropopliteal bypass              | % (n/N)            | 22.8% (72/316)  | 14.4% (19/132)  | 28.8% (53/184)  | 0.0027  |
| Femo-femoral cross bypass           | % (n/N)            | 0.6% (2/316)    | 0.8% (1/132)    | 0.5% (1/184)    | 1.0000  |
| Leg of bifurcation stentgraft       | % (n/N)            | 0.3% (1/316)    |                 | 0.5% (1/184)    | 1.0000  |
| Ileofemoral bypass                  | % (n/N)            | 0.3% (1/316)    |                 | 0.5% (1/184)    | 1.0000  |
| Deep femoral artery                 | % (n/N)            | 10.1% (32/316)  | 15.2% (20/132)  | 6.5% (12/184)   | 0.0142  |
| In-stent occlusion                  | % (n/N)            | 23.4% (74/316)  | 24.2% (32/132)  | 22.8% (42/184)  | 0.7888  |
| Additional infrapopliteal occlusion | % (n/N)            | 61.7% (195/316) | 62.9% (83/132)  | 60.9% (112/184) | 0.7266  |
| Number of patent calf vessels       | n                  | 316             | 132             | 184             | 0.6844  |
|                                     | Mean ± SD          | 0.9 ± 1.1       | 0.9 ± 1.1       | 1.0 ± 1.1       |         |
|                                     | Median             | 0.0             | 0.0             | 0.0             |         |
|                                     | Range              | 0.0, 3.0        | 0.0, 3.0        | 0.0, 3.0        |         |
| ABI before treatment                | n                  | 309             | 129             | 180             | 0.2715  |
|                                     | Mean ± SD          | 0.1 ± 0.2       | 0.12 ± 0.16     | 0.14 ± 0.17     |         |
|                                     | Median             | 0.0             | 0.0             | 0.0             |         |
|                                     | Range              | 0.0, 0.6        | 0.0, 0.6        | 0.0, 0.6        |         |